Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Our purpose is to drive bold pursuits in science with a promise to always put patients first.
Check-Cap is developing C-Scan, a novel x-ray imaging capsule that is designed to scan the colon and detect polyps without the need for a cathartic prep. Our aim is to bring a patient friendly system for colon cancer prevention, detecting polyps in the colon, before they become cancerous.
Screening for colon cancer can save lives, and early detection of polyps can prevent cancer. The current adherence to colon cancer screening in the US is approx. 60%, and worldwide, the adherence is substantially lower. This is due to several factors, among which, colon preparation and fear of colonoscopy.
CLASSEEK BIO developed a state-of-the-art, inexpensive, AI-based machine learning toolset for identifying individuals who are at high risk of having colorectal cancer (CRC) in one or two years (as opposed to other methods, e.g., genetic profiling).
Our toolset includes an algorithm that analyses the results of routine conventional blood tests already stored in HMO databases. The algorithm indicates specific individuals at high risk who should be tested by colonoscopy in the near future.
ECS-Progastrin, an innovative and ground breaking biotech company specializing in oncology. ECS-Progastrin develops and markets revolutionary solutions based on the detection of hPG80 (Progastrin), a novel ubiquitous cancer blood biomarker. This biomarker is specifically released in the blood by various types of tumors at early stages, making it a highly valuable tool for early detection and cancers monitoring.
Our first two products based on this biomarker; DxPG80.lab for follow-up and DxPG80.smart for early detection, are now commercialized, CE marked and available to the medical community.
These solutions are affordable, simple, reliable and ready to be used by physicians.
Cancer is often detected too late. At Exact Sciences, we work to deliver life-changing innovations in earlier cancer detection to help people make more effective decisions. Alongside our visionary collaborators, and in partnership with communities, we unite the best resources to help advance the fight against cancer, together.
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science.
We are Janssen. We collaborate with the world for the health of everyone in it. Follow us at www.twitter.com/JanssenEMEA. Janssen Research & Development, LLC and Janssen-Cilag International NV are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
VBL Therapeutics, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. VBL’s lead oncology product candidate, ofranergene-obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid-tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated activity signals in an “all-comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene-obadenovec is currently being studied in a Phase 3 potential-registration trial for platinum-resistant ovarian-cancer.